TG Therapeutics (NASDAQ:TGTX – Get Free Report) released its earnings results on Monday. TG Therapeutics Stock Up 0.7%TG Therapeutics stock traded up $0.32 during trading hours on Wednesday, reaching $49.06. TG Therapeutics Company Profile(Get Free Report)TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S. Recommended StoriesReceive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.